Events and Presentations

Nabriva Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference

Events and Presentations | Investor News | Shareholder Information
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Press Releases
DateTitle  
04/19/17Nabriva Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., April 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Deutsche Bank 42nd Annual Health Ca... 
 Printer Friendly Version
04/17/17Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer
VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV) (“Nabriva AG”) announced that its supervisory board and management board approved the relocation of the holding company of Nabriva AG and its subsidiaries (“Nabriva Group”) from Austria to Ireland (the “Redomiciliation Transaction”). The Redomiciliation Transaction will be effected by the exchange of American depositary shares (“Nabriva AG ADSs”) and shares (the “Exchange Offer”) of Nabriva AG for shares ... 
 Printer Friendly Version
04/13/17Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
Nine abstracts support potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa., April 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will present data a... 
 Printer Friendly Version
04/11/17Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia
VIENNA, Austria and KING OF PRUSSIA, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has completed enrollment in its first lefamulin evaluation against pneumonia (LEAP 1) Phase 3 clinical trial. LEAP 1, which is designed to assess the efficacy ... 
 Printer Friendly Version
03/27/17Nabriva Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., March 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Needham and Company 16th Annual Hea... 
 Printer Friendly Version
03/24/17Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results
VIENNA, Austria and KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its financial results for the year ended December 31, 2016. “For the last 12 months, we have been executing o... 
 Printer Friendly Version
02/27/17Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Cowen and Company 37th Annual Health... 
 Printer Friendly Version
02/08/17Nabriva Therapeutics to Participate in Two Investor Conferences in February
VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., Chief Executive Officer of Nabriva Therapeutics, will provide a company overview and business update at the following conferences in February. ... 
 Printer Friendly Version
02/02/17Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
LEAP 1 top-line efficacy and safety data expected in 3Q17 VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that following a blinded interim analysis, an independent committee recommended no sample size adjustment fo... 
 Printer Friendly Version